Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nasal spray vaccine aims to stop COVID-19 at the source

NCT ID NCT07703475

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study tests a new type of COVID-19 booster vaccine given as a nasal spray. The vaccine uses a weakened live virus to train the immune system, potentially offering stronger protection in the nose and throat where the virus enters. Researchers are enrolling 80 healthy adults aged 18–64 who have already been vaccinated against COVID-19 to check the vaccine's safety and how well it triggers an immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a live-attenuated SARS-CoV-2 vaccine called RVX-sCPD9, given as a nasal spray
What this could lead to
If successful, this nasal vaccine could provide a more convenient and potentially more effective booster against COVID-19, possibly reducing viral spread.
What could go wrong
This is an early Phase 1 trial with only 80 participants, so safety and immune response are still unproven. The live virus in the vaccine carries a small risk of causing mild COVID-like symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.